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NAFLD is a polygenic condition but the individual and cumulative contribution of identified genes 
remains to be established. To get additional insight into the genetic architecture of NAFLD, GWAS-
identified GCKR, PPP1R3B, NCAN, LYPLAL1 and TM6SF2 genes were resequenced by next generation 
sequencing in a cohort of 218 NAFLD subjects and 227 controls, where PNPLA3 rs738409 and MBOAT7 
rs641738 genotypes were also obtained. A total of 168 sequence variants were detected and 47 were 
annotated as functional. When all functional variants within each gene were considered, only those in 
TM6SF2 accumulate in NAFLD subjects compared to controls (P = 0.04). Among individual variants, 
rs1260326 in GCKR and rs641738 in MBOAT7 (recessive), rs58542926 in TM6SF2 and rs738409 in 
PNPLA3 (dominant) emerged as associated to NAFLD, with PNPLA3 rs738409 being the strongest 
predictor (OR 3.12, 95% CI, 1.8-5.5, P < 0.001). A 4-SNPs weighted genetic risk score value >0.28 was 
associated with a 3-fold increased risk of NAFLD. Interestingly, rs61756425 in PPP1R3B and rs641738 in 
MBOAT7 genes were predictors of NAFLD severity. Overall, TM6SF2, GCKR, PNPLA3 and MBOAT7 were 
confirmed to be associated with NAFLD and a score based on these genes was highly predictive of this 
condition. In addition, PPP1R3B and MBOAT7 might influence NAFLD severity.
Non-alcoholic fatty liver disease (NAFLD), is a multifactorial disease characterized by an increased hepatic tri-
glyceride content (>5.5% of liver weight) in the absence of an excess of alcohol consumption, HVC infection, 
familial hypobetalipoproteinemia or endocrine disorders1,2. NAFLD, which currently represents the leading cause 
of liver damage in developed countries3, has well established risk factors such as insulin resistance associated with 
overweight, physical inactivity and type 2 diabetes mellitus (T2DM)4. However, epidemiological, familial and 
twin studies have clearly indicated that the risk of NAFLD has also a strong genetic component5.
In the last few years, a large number of genetic investigations, employing single candidate gene as well as 
genome-wide association studies (GWAS) strategies, have provided compelling evidence that several gene var-
iants are associated with NAFLD5. In particular, the rs738409 C > G change in the Patatin-like Phospholipase 
domain-containing 3 (PNPLA3) gene, coding for the I148M protein variation, has been identified as a major 
determinant of inter-individual and ethnicity-related differences in hepatic fat content6,7. The mechanism by 
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which this substitution induces liver fat is related to an impaired hepatocellular triglycerides hydrolysis and 
increased lipogenesis associated to the 148 M allele8,9. More recently, the Transmembrane 6 Superfamily Member 
2 (TM6SF2) E167K variant has also been shown to increase NAFLD susceptibility10. This effect appears to be due 
to an impaired mobilization of neutral lipids for very low-density lipoprotein (VLDL) assembly and secretion by 
the liver in E167K carriers11–13.
Furthermore, GWAS studies have indicated additional loci whose involvement in the pathogenesis of liver 
steatosis is less established. In particular, Speliotes E.K. et al.14 reported that variants in Protein Phosphatase 
1 Regulatory Subunit 3B (PPP1R3B), Glucokinase Regulatory Protein (GCKR), Neurocan (NCAN) and 
Lysophospholipase Like 1 (LYPLAL1) genes were associated to the presence of NAFLD. Finally, based on results 
obtained in patients with alcoholic liver disease (ALD)15, Mancina et al.16 demonstrated an association between 
the rs641738 in the membrane Bound O-Acyltransferase Domain Containing 7 gene (MBOAT7) and the occur-
rence and progression of NAFLD. The minor allele (T) was significantly associated with high liver fat content only 
in European Americans, but not in African Americans and Hispanics. Moreover, this variant showed an additive 
effect with PNPLA3 and TM6SF2 single nucleotide polymorphisms (SNPs) in determining the risk of liver fibro-
sis17. Overall, these findings clearly indicate that the genetic predisposition to NAFLD results from a combination 
of several variants, which may influence different steps of hepatic lipid and carbohydrate metabolism18.
Despite this wealth of knowledge, the proportion of genetic risk of NAFLD explained by the identified loci 
remains modest (<5%). This might be because the majority of GWAS tag SNPs are common and/or lie in inter-
genic or intronic regions19. Moreover, GWAS did not capture rare or low frequency risk variants with moderate/
strong effects, which could explain a part of this missing heritability. An effective way to overcome these limita-
tions is to re-sequence the entire coding portion of candidate genes to capture all non-genotyped risk alleles. This 
strategy has already been successfully employed for various conditions where subjects with well distinct pheno-
types were genotyped20. In addition, the candidate genes resequencing strategy, by providing a comprehensive 
evaluation of the polygenic architecture of NAFLD, would allow to weighing the overall as well as the individual 
contribution of different variants to the risk of this complex trait.
Here we provide the evaluation of genetic determinants of NAFLD using the sequencing analysis of candidate 
genes emerged from GWAS. To this aim, we have re-sequenced the coding regions of GCKR, PPP1R3B, LYPLAL1, 
NCAN and TM6SF2 genes in NAFLD and control subjects, where PNPLA3 rs738409 and MBOAT7 rs641738 
genotypes were also obtained.
The association of individual variants with NAFLD has been evaluated by using logistic regression analysis. 
Furthermore, following the logic of recent studies that have tested in complex disorders the combined impact of 
multiple genetic variants21, we determined a polygenic score for NAFLD based on identified risk alleles.
Results
Subjects characteristics. Baseline characteristics of study participants are reported in Table 1. Compared 
with controls, NAFLD subjects were older, showed higher indices of adiposity and increased plasma triglycer-
ides (TG) and reduced HDL-C concentrations (all P < 0.001). Also fasting plasma levels of glucose, insulin and 
HOMAIR values were significantly higher in NAFLD compared with control subjects (all P < 0.001). As expected, 
the prevalence of T2DM and metabolic syndrome (MetS) was higher in NAFLD than in controls. Moreover, 
subjects with NAFLD were more frequently smokers and hypertensives (P < 0.001). A statistically significant 
elevation of ALT (P < 0.001), AST (P = 0.008) and γGT (P < 0.001) were seen in NAFLD compared with control 
subjects. Among NAFLD subjects, 164 (76.3%) were classified as having moderate to severe liver steatosis accord-
ing to Hamaguchi’s criteria.
DNA re-sequencing. Overall, 168 variants were identified, of which 100 were intronic and 68 exonic. Among 
exonic variants, 43 were nonsynonymous (NS), 2 nonsense, 2 frameshift and 21 synonymous (Supplementary 
Table S1). Thirty one (65.9%) were classifiable as rare (MAF < 0.01), 5 (10.6%) as low frequency/less common 
(0.01 ≤ MAF < 0.05) and 3 (6.4%) common variants (MAF ≥ 0.05). Six exonic variants (12.7%) were not been 
previously reported in dbSNP and thus submitted to EXAC database (http://exac.broadinstitute.org). Forty-seven 
variants were annotated as functional (nonsense, frameshift and nonsynonymous), 23% in GCKR, 14.8% in 
LYPLAL1, 34% in NCAN, 8.5% in PPP1R3B and 19.4% in TM6SF2 genes. These variants were considered for 
further analyses.
The list of identified variants with their in silico prediction of deleteriousness is reported in the Supplementary 
Table S2.
Enrichment of gene variants in NAFLD and controls. Figure 1 shows the percentage of subjects car-
rying at least one functional variant within each gene in study groups. Overall, 80% of subjects with NAFLD 
were positive for at least one variant in GCKR, 31% for LYPLAL1, 15% for NCAN, 8% for PPP1R3B and 14% 
for TM6SF2 genes. Among controls, 79% were positive for at least one variant in GCKR, 34% in LYPLAL1, 10% 
in NCAN, 4% in PPP1R3B and 8% in TM6SF2 genes. Although variants in NCAN and PPP1R3B appeared to 
be more frequent in cases compared with controls, only those in TM6SF2 reached the statistical significance 
(OR = 2.0, 95% CI, 1.0-4.0, P = 0.04). However, after correction for multiple comparisons, the association of 
TM6SF2 gene was no longer significant.
Association of individual variants with NAFLD. In order to investigate the effect of genetic variants 
on NAFLD susceptibility, each identified sequence variation was included in a stepwise regression analysis. As 
all study subjects were also genotyped for the PNPLA3 rs738409 and MBOAT7 rs641738, these variants were 
also considered. As reported in Table 2, rs1260326 C/T in GCKR, rs58542926 C/T in TM6SF2, rs738409 C/G in 
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PNPLA3 and MBOAT7 rs641738 T allele emerged as significantly associated with the presence of NAFLD (all 
P ≤ 0.05).
After adjustment for covariates such as age, gender, body mass index (BMI), HOMAIR and TG, a dominant 
model of inheritance best explained the association with NAFLD of rs738409 C/G PNPLA3 (OR = 3.2, 95% 
CI, 1.79-5.59, Padj < 0.001). Conversely, the association of rs1260326 C/T GCKR (OR = 1.9, 95% CI, 1.12-3.46, 
Padj = 0.018) fitted better with a recessive model of inheritance. A similar trend was observed for TM6SF2 
rs58542926 T and MBOAT7 rs641738 T alleles, although with a borderline level of significance. However, it must 
be noted that a real estimation of the effect of TM6SF2 variant in the dominant or recessive model could not be 
provided because of the low frequency of the T-allele (167 K) (only two homozygous subjects). Thus, all calcula-
tions were based on the dominant model of inheritance.
When these 4 NAFLD-associated variants were tested together, they explained, overall, about 7% of the genetic 
risk of NAFLD and the rs738409 in PNPLA3 ranked as the strongest predictor (OR = 3.12, 95% CI, 1.8-5.5, 
NAFLD Controls P
N 218 227
Age (years) 54 (46–60) 49.7 (41–58) <0.001
Gender(M/F)(%) 69.7/30.3 63.0/37.0 ns
BMI (kg/m2) 29.2 (26.5–32.5) 24.9(23.2–27.1) <0.001
Waist circumference, (cm) 106.1 ± 13.5 91.2 ± 9.91 <0.001
Smokers, n (%) 66 (30.6) 44 (19.7) 0.043
T2DM, n (%) * 54 (24.8) 3 (1.3) <0.001
MetS, n (%) 126 (57.8) 18 (7.9) <0.001
Statins, n (%) 50 (22.9) 28 (12.3) 0.003
Systolic BP (mmHg) 130 (120–140) 120 (110–135) <0.001
Diastolic BP (mmHg) 80 (80–85) 80 (70–80) <0.001
TC (mg/dl) 199.8 ± 41.1 201.0 ± 38.2 ns
TG (mg/dl) 134 (99–183) 87 (68–116) <0.001
HDL-C (mg/dl) 44 (37.5–54) 58 (49–68) <0.001
LDL-C (mg/dl) 125.3 ± 60.2 121.7 ± 33.9 ns
Fasting Blood Glucose (mg/dl) 95 (85–112) 85 (77–90) <0.001
Fasting Insulin (UI/L) 12.7 (8.9–19.9) 5.7 (4.0–7.8) <0.001
HOMAIR 3.0 (2.1–5.0) 1.14(0.77–1.65) <0.001
ALT (UI/I) 27 (19–42) 15 (12–20) <0.001
AST (UI/I) 23 (19–30) 21 (18–26) 0.008
γ-GT (UI/I) 27 (17–41) 19 (15–26) <0.001
Table 1. Clinical and metabolic characteristics of study subjects. Data are expressed as percentage, mean (±SD) 
and median (25th–75th percentile range) as appropriate. Abbreviations: AST, aspartate aminotransferase; ALT, 
alanine aminotransferase; BMI, body mass index; BP, blood pressure; y-GT, gamma glutamyl transferase; HDL, 
high density lipoprotein; HOMA-IR, homeostasis model of insulin resistance (fasting plasma glucose in mg/dL 
x fasting insulin in U/L)/405; LDL, low density lipoprotein; MetS, metabolic syndrome (defined by the NCEP-
ATP III Expert Panel criteria43); NAFLD, non-alcoholic fatty liver disease; TC, total cholesterol; T2DM, type 2 
diabetes mellitus.
Figure 1. Enrichment of gene variants in NAFLD and controls. Percentage of subjects carrying at least one 
functional variant. In each group (NAFLD cases and controls) we count the number of subjects positive for at 
least one functional variant within each gene. *χ2 = 4.14, P = 0.04. *Odd Ratio unadjusted: OR = 2.0, 95% CI, 
1.0-4.0, P = 0.04. In the model were included all subjects observed as carrying at least one functional variant per 
gene in NAFLD patients vs. controls.
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P < 0.001) when adjusted for conventional risk factors (Table 3). Hosmer-Lomeshow goodness of fit test showed 
that the model combining both genetic and non-genetic variables explained the observed data (X26 = 16.45; 
P = 0.036) with a predictive ability of 58.2%. The results did not change even after including or excluding from 
the model plasma TG and glucose levels. It is worth to mention that when in this model HOMAIR was removed 
from covariates, TM6SF2 T allele reemerged as a significant predictor of NAFLD (OR = 3.6, 95% CI, 1.40-9.27, 
Padj = 0.008). This might be explained by the observation that carriers of this variant showed higher levels of 
HOMAIR compared to non-carriers (3.2 (2.1-6.0) vs. 1.43 (0.88-1.93), P = 0.002, respectively).
Next, we examined the proportion of risk of NAFLD conferred by gene-gene and gene-environment inter-
action. Although we did not identify any gene-gene synergy, PNPLA3 rs738409 showed a significant inverse 
interaction with TG (OR = 0.9, 95% CI, 0.97-0.99, P = 0.0021) and HOMAIR (OR = 0.33, 95% CI, 0.17-0.62, 
P = 0.001) but not with age, gender or BMI. Moreover, we observed a barely significant interaction between 
TM6SF2 polymorphism and BMI (OR = 0.8, 95% CI, 0.63-1.01, P = 0.07). Conversely, no interactions between 
GCKR rs1260326 or MBOAT7 rs641738 and conventional NAFLD risk factors were observed.
Association of genetic variants with metabolic traits. After stratifying the study population by 
TM6SF2 rs58542926 (dominant model), GCKR rs1260326 (recessive model), PNPLA3 rs738409 (dominant 
model) and MBOAT7 rs641738 (recessive model) genotypes, difference in clinical, anthropometric and bio-
chemical indices were found across groups. NAFLD individuals carrying the minor T allele of rs58542926 
(167 K) (N = 25) showed lower plasma total cholesterol (TC) (Padj = 0.021) and TG (Padj = 0.002) and higher 
AST (Padj = 0.006) and ALT (Padj = 0.012) levels when compared with NAFLD patients with wild-type C allele 
(N = 193). More importantly, the association with TC and TG levels was unchanged after adjustment for BMI, 
T2DM or statin therapy (all Padj < 0.05). Similarly, NAFLD patients carrying CG or GG PNPLA3 genotypes 
(N = 126) compared with non-carriers (N = 92) showed, lower BMI (Padj = 0.001), lower TG levels (Padj = 0.001) 
and HOMAIR (Padj = 0.004) and higher AST levels (Padj < 0.001). Notably, the association of [CG + GG] genotypes 
with TG levels persisted even after adjustment for BMI and diabetes (Padj = 0.01). On the contrary, no differences 
Gene SNP ID
NAFLD 
(N/%)
Controls 
(N/%) Genotype model
N = 218 N = 227 χ2 P-value OR (95% CI)
Unadjusted 
P-value OR (95% CI)
Adjusted* 
P-value
PNPLA3 rs738409
CC 92 (42.2) 123 (54.2)
CG 91 (41.7) 56 (24.7) 2.2 (1.41–3.33) <0.001 2.5 (1.30–4.85) 0.006
GG 35 (16.1) 48 (21.1) 14.6 0.001 0.9 (0.58–1.62) 0.9 4.2 (2.07–8.85) <0.001
Dominant Model CG + GG 126 (57.8) 104 (42.8) 6.39 0.014 1.6 (1.11–2.35) 0.012 3.2 (1.79–5.59) <0.001
Recessive Model GG 35 (16.1) 48 (21.1) 1.89 0.168 0.7 (0.44–1.15) 0.16 3.0 (1.55–5.93) 0.001
GCKR rs1260326
CC 43 (19.7) 49 (21.6)
CT 90 (41.3) 123 (54.2) 0.8 (0.51–1.36) 0.46 0.8 (0.44–1.74) 0.69
TT 85 (39.0) 55 (24.2) 11.7 0.003 1.8 (1.03–2.99) 0.04 1.8 (0.86–3.73) 0.11
Dominant Model CT + TT 175 (80.3) 178 (78.8) 0.23 0.62 1.1 (0.70–1.77) 0.62 1.2 (0.62–2.24) 0.61
Recessive Model TT 85 (39.0) 55 (24.2) 11.2 0.001 2.0 (1.32–3.00) 0.001 1.9 (1.12–3.46) 0.018
TM6SF2 rs58542926
CC 161 (88.0) 214 (94.3)
CT 25 (11.5) 11 (4.8) 2.5 (1.20–5.25) 0.014 2.4 (0.91–6.65) 0.07
TT — 2 (0.9) 8.349 0.015 —
Dominant Model CT + TT 25 (11.5) 13 (5.7) 4.693 0.041 2.1 (1.06–4.28) 0.033 2.2 (0.84–5.77) 0.10
MBOAT7 rs641738
CC 61 (28.0) 78 (34.4)
CT 105 (48.2) 111 (48.9) 1.21 (0.78–1.85) 0.38 0.90 (0.49–1.65) 0.74
TT 52 (23.9) 38 (16.7) 4.243 0.120 1.75 (1.02–2.99) 0.04 1.75 (0.82–3.71) 0.14
Dominant Model CT + TT 157 (72.0) 149 (65.6) 2.107 0.147 1.34 (0.90–2.02) 0.14 1.09 (0.62–1.92) 0.74
Recessive Model TT 52 (23.9) 38 (16.7) 3.487 0.062 1.55 (0.97–2.48) 0.06 1.86 (0.96–3.59) 0.06
Table 2. Genotype frequencies and Odds Ratios (ORs) of variants associated with NAFLD. Data express 
the absolute numbers and percentages of cases and controls. Only variants showing a P value ≤ 0.06 were 
reported in the table. *Models were adjusted by Age (years), Gender (M/F), BMI (kg/m2), HOMAIR, TG (mg/
dl) and genotypes were considered as dominant or recessive (Logistic Regression analysis, Enter Method). 
Abbreviations: BMI, Body Mass Index, GCKR, glucokinase (hexokinase 4) regulator gene, HOMAIR, 
homeostasis model of insulin resistance, MBOAT7, membrane-bound O-acyltransferase domain-containing 7 
gene, NAFLD, non-alcoholic fatty liver disease. PNPLA3, Patatin-like phospholipase domain-containing protein 
3 gene, TM6SF2, Transmembrane 6 superfamily Member 2 gene, TG, Triglycerides, OR, odd ratio, 95% CI,  
95% CI confidence interval.
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in clinical, anthropometric and biochemical indices were found across the GCKR rs1260326 or the MBOAT7 
rs641738 genotypes in patients with NAFLD.
Genetic risk score (GRS) and the risk of NAFLD. The median values of weighted and unweighted 
4-SNP GRS were significantly higher in NAFLD than in controls (median unweighted GRS: 3 (2–4) vs. 2 (2–3), 
P = 0.001; median weighted GRS: 0.38 (0.17–0.50) vs. 0.18 (0.12–0.44), P = 0.03, respectively). When weighted 
4-SNP GRS values was distributed according to tertiles (Fig. 2, Panel a), the prevalence of NAFLD significantly 
increased along with increasing tertiles (χ2 = 14.9, P = 1 × 10-4) and the risk was significantly higher for GRS 
values above >0.28 (corresponding to the 2th tertile) (Fig. 2, Panel b). This trend persisted even after adjustment 
for age, gender, BMI, HOMAIR and TG levels.
Association of genetic variants with severity of NAFLD. The association of genetic variants with 
the ultrasound-defined severity of NAFLD is reported in Table 4. A NGS-identified variant in PPP1R3B gene 
(rs61756425 G/T p.S41R) emerged as more frequent in NAFLD patients than in controls (χ2 = 16.11, P < 0.001) 
and as the strongest independent genetic predictor of severe hepatic steatosis (OR = 32.6, 95% CI, 4.22-251.4, 
Padj = 0.001). This association was maintained even after bootstrap correction (two-tailed Padj = 0.001). Similarly, 
the rs641738 in MBOAT7 gene showed a significant effect on NAFLD severity (OR = 2.6, 95% CI, 1.10-6.28, 
Padj = 0.022). As expected, age, BMI and HOMAIR were detected as the non-genetic significant predictors of 
severity of NAFLD.
Gene, SNP ID β OR (95% CI) P -value *Padj-value
PNPLA3, rs738409
Dominant Model 1.14 3.12 (1.8–5.5) <0.001 0.001
GCKR, rs1260326
Recessive Model 0.64 1.90 (1.1–3.4) 0.028 0.039
Age (years)
BMI (kg/m2)
HOMAIR
TG (mg/dl)
0.02
0.19
0.71
0.01
1.02 (1.00–1.05)
1.21 (1.11–1.31)
2.03 (1.56–2.65)
1.01 (1.00–1.01)
0.040
<0.001
0.001
0.001
0.039
0.001
0.010
0.005
Table 3. Independent associations of genetic variants with NAFLD. Stepwise regression analysis (Forward-
Wald Statistic) were used to test the association of clinical and genetic factors with NAFLD. In the model were 
included: Age (years), Gender (M/F), BMI (kg/m2), HOMAIR, TG (mg/dl), rs738409 PNPLA3 (dominant 
model), rs1230326 GCKR (recessive model), rs58542926 TM6SF2 (dominant model) and rs641738 MBOAT7 
(recessive model). Only significant variables were reported. *P was adjusted for multiple comparisons by using 
the bootstrap method. Abbrevations: BMI, Body Mass Index, GCKR, glucokinase (hexokinase 4) regulator gene, 
HOMAIR, homeostasis model of insulin resistance, PNPLA3, Patatin-like phospholipase domain-containing 
protein 3 gene, TG, Triglycerides, OR, odd ratio, 95% CI, 95% CI confidence interval.
Figure 2. Association of weighted GRS with the risk of NAFLD. (a) Distribution of tertiles of weighted 4-SNP 
GRS in NAFLD patients; (b) NAFLD Odds Ratio (OR) adjusted for age, gender, BMI, HOMAIR and TG across 
tertiles of weighted 4-SNP GRS. The weighted 4-SNP GRS was calculated by multiplying the sum of the number 
of risk alleles (0–2) with the corresponding effect sizes per allele as obtained from the Dallas Heart Study22. 
Tertiles boundaries were defined as follow: T1 GRS ≤0.1775; T2 GRS >0.1775 and ≤0.3877; T3 GRS >0.3887. 
(a) Padj for trend. In the model were included age (years), gender (M/F), BMI (kg/m2), HOMAIR and TG (mg/dl) 
and tertiles of weighted 4-SNSP GRS (χ2 Pearson followed by Stepwise Regression analysis). (b) Adjusted 
NAFLD OR. In the model were included age (years), gender (M/F), BMI (kg/m2), HOMAIR and TG (mg/dl) and 
tertiles of weighted GRS (Stepwise Regression analysis, Forward-Wald Statistic).
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Discussion
NAFLD is a complex trait whose genetic component has been explored by many studies using different 
approaches18. Although several genes and genetic variants have been identified as involved in the occurrence of 
the disease, not all were consistently confirmed. Moreover, their combined effect on NAFLD susceptibility has 
rarely been explored.
In agreement with previous studies6,7,10,14,16,18,22,23, we found that PNPLA3 rs738409, GCKR rs1260326, 
TM6SF2 rs58542926 and MBOAT7 rs641738, but not the other GWAS identified variants14, were genetic contrib-
utors to NAFLD in our cohort.
Hepatic fat accumulation results from an imbalance between TGs acquisition, synthesis, utilization and secre-
tion24 and, as yet described, the PNPLA3 I148M, TM6SF2 E167K and GCKR P446L polymorphisms promote 
steatosis through interaction with distinct metabolic mechanisms. Both genotypes in PNPLA3 and TM6SF2 
influence the ability to export very low-density lipoproteins (VLDLs) from the liver8–13,17. In addition, p.P446L 
is a loss-of-function variant that results in increased phosphorylation of glucose25, glycolysis and fatty acid syn-
thesis26. Similarly, recent findings indicated that the rs641738 in MBOAT7 gene, by decreasing the expression 
of MBOAT7 enzyme, unfavorably affects the acyl remodeling of phospholipid acyl-chain in the liver16. Taken 
together, these data indicate that a biologically plausible mechanism by which these gene variants directly influ-
ence the development of NAFLD exists. On the other hand, they further support the notion that the impaired 
lipid handling by hepatocytes has a major causal role in the pathogenesis of NAFLD.
When considered on individual basis, PNPLA3 variant ranked as the strongest genetic predictor of NAFLD 
followed by GCKR. In contrast, a weaker association was detected for TM6SF2 and MBOAT7. These observations 
could be partially explained by the low frequency of TM6SF2 risk allele as compared to PNPLA3 risk allele27. In 
addition, the finding that NAFLD carriers of the TM6SF2 167K allele have increased levels of HOMAIR might 
have masked the effect of this variant on NAFLD risk due to the predominant role of insulin resistance in the 
pathogenesis of NAFLD28,29. The finding on MBOAT7 is more difficult to be interpreted. However, it must be 
pointed out that this gene has not been consistently associated with NAFLD in all ethnic groups16 and, when a 
role was demonstrated, the MBOAT7 rs641738 variant showed the smallest effect in predisposing to fatty liver22.
Another interesting aspect of our findings is that, in agreement with previous studies, they do not fully sup-
port the notion that common variants are the major contributors to NAFLD susceptibility20,30. In fact, in our 
cohort the rs58542926 T allele (MAF ~ 7%) displayed a 2.5-fold risk of hepatic steatosis higher than the 1.9 fold 
risk associated to GCKR T allele (MAF ~ 42%). Thus, according to the hypothesis of Manolio T.A. et al.20, the 
lower frequency of rs58542926 in the general population could be the reason why we observed a larger effect 
of TM6SF2 T allele differently to GCKR TT genotype in the occurrence of NAFLD. Moreover, it is important to 
consider that in our cohort 55% of rs1260326 TT carriers were also heterozygous or homozygous carriers for the 
PNPLA3 rs738409, thus suggesting that the association with GCKR might be due to genetic bias.
Nevertheless, we confirmed that these genetic variants might act in an additive fashion. In fact, by using a 
4-SNP GRS, we observed that the full combination of risk alleles increased the probability of hepatic steatosis 
up to 5 fold and this effect was present even after adjustment for traditional risk factors. These results emphasize 
the importance to consider a multiplicity of potentially involved gene variants when studying the genetic epide-
miology of a common complex trait as NAFLD31,32. Of note, only four previous studies, carried out in different 
ethnic groups, have considered the combined effect of different genetic variants in determining fatty liver17,22,33,34. 
However, these Authors only performed genotyping tests for some of all previously GWAS-identified SNPs 
without exploring the entire coding region of NAFLD-associated loci. In addition, Krawczyk M. et al.17 concen-
trated their attention in evaluating the effect of the number of risk alleles (unweighted GRS) only on the grade 
of steatosis and fibrosis. Although our results need to be further evaluated in larger populations, they highlight 
the possibility to identify individuals at high risk of NAFLD by genotyping these genetic risk factors. Notably, 
EASL–EASD–EASO Clinical Practice Guidelines35 already suggest genotyping for TM6SF2 and PNPLA3 to select 
patients with higher risk of hepatic steatosis.
Our results indicated that the model including genetic and non-genetic variables accounts for the 58.2% of 
NAFLD heritability. These findings further confirm that the hepatic steatosis is a dynamic process that results 
from a constant interplay between genetic and environmental determinants and its heritability is not only due 
to the primary effect of PNPLA3, TM6SF2, GCKR and MBOAT7 genotypes but also by the secondary effects 
NAFLD degree Variables β OR (95% CI) P-value *Padj-value
Severe
PPP1R3B, rs61756425
MBOAT7, rs641738
Gender (F)
BMI (kg/m2)
HOMAIR
3.48
0.96
1.26
0.23
0.60
32.6 (4.22–251.4)
2.6 (1.10–6.28)
0.3 (0.11–0.70)
1.2 (1.15–1.38)
1.8 (1.51–2.22)
0.001
0.029
0.006
<0.001
<0.001
0.001
0.022
0.027
0.001
0.001
Table 4. Predictors of NAFLD severity in the whole cohort. Stepwise regression analysis (Forward-Wald 
Statistic) were used to test the association of clinical and genetic factors with NAFLD. In the model were 
included: Age (years), Gender (M/F), BMI (kg/m2), HOMAIR, TG (mg/dl), rs738409 PNPLA3 (dominant 
model), rs1230326 GCKR (recessive model), rs58542926 TM6SF2 (dominant model) and rs641738 MBOAT7 
(recessive model). Only significant variables were reported. *P was adjusted for multiple comparisons by 
using the bootstrap method. Abbrevations: BMI, Body Mass Index, HOMAIR, homeostasis model of insulin 
resistance, MBOAT7, membrane-bound O-acyltransferase domain-containing 7 gene, NAFLD, Non-alcoholic 
fatty liver disease, TG, Triglycerides, OR, odd ratio, PPP1R3B, Protein Phosphatase 1 Regulatory Subunit 
3B, 95% CI, 95% CI confidence interval.
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of non-genetic factors. In contrast with Stender S. et al.36, we did not find any synergy between adiposity and 
genotypes. The lack of interaction with BMI could be related to the fact that we did not quantify the intrahepatic 
triglyceride content (IHTG) but we considered hepatic steatosis as binary outcome variable in a case-control 
study37. Thus, while we described an inverse interaction effect between PNPLA3 genotypes HOMAIR and TG in 
predicting the higher risk of hepatic steatosis, the modest sample size could be the reason why we did not identi-
fied synergy with BMI37.
Finally, we found a significant association between the PPP1R3B rs61756425 and MBOAT7 rs641738 variants 
in predicting the severity of hepatic steatosis. Although MBOAT7 has been previously associated with progres-
sion of NAFLD16,17,38, the observation on PPP1R3B is novel. This variant has never been identified in GWAS nor 
associated to severity of NAFLD. This is probably due to its very low frequency in the population, thus support-
ing the notion that the re-sequencing of entire coding region of candidate genes may capture non-genotyped 
low-frequency risk alleles20,39. It must be, however, pointed out that the high value with a wide 95% CI of OR asso-
ciating PPP1R3B rs61756425 with NAFLD severity may suggest a low level of accuracy of this estimate, mainly 
due to the very low number of carriers of this variant. Therefore, additional evaluations in much larger cohorts 
are needed. On the other hand, very recent observations have challenged the role of PPP1R3B as genetic factor 
predisposing to liver fat accumulation. In fact, Stender S. et al.40 have shown in mice that the lack of PPP1R3B 
was associated with reduced glycogen and unchanged fat liver content; conversely, the hepatic overexpression 
of PPP1R3B caused accumulation of hepatic glycogen and elevated ALT levels without affecting triglycerides 
accumulation. Based on this evidence, the role of PPP1R3B rs61756425 variant in liver disease surely requires 
additional evaluation with a direct confirmation of liver histological changes associated with this variant.
Strengths and limitations of our study must be acknowledged. To the best of ours knowledge, this is the 
first study reporting a comprehensive evaluation of sequence variants detectable in the entire coding regions of 
NAFLD-associated loci. This allowed evaluating the individual as well as the cumulative contribution of iden-
tified variants to the risk of NAFLD. However, it must be recognized that the definition of NAFLD was based 
on ultrasound and not on direct measurement of hepatic fat content with a more accurate methods such as the 
liver magnetic resonance. In addition, the size of the sequencing sample was modest so that some relevant rare 
variant might have been missed. To this regard, it is noteworthy that the power analysis indicated that our exper-
imental design was able to identify low frequency variants and to detect moderate effects size. More, we did not 
re-sequenced the PNPLA3 and the MBOAT7 genes. For the former, we have considered the 148 M variant as it 
represents the only variant in this gene associated to hepatic fat content41. In fact, Donati B et al. by re-sequencing 
a cohort of children with early-onset histological NAFLD did not find any additional predictive rare variant in 
the PNPLA3 gene41. In addition, we genotyped only the MBOAT7 rs641738 variant as it was reported to display 
the major role in NAFLD16,42. Finally, an additional limitation of our study was the lack of replication of iden-
tified rare variants in an independent sample. However, it must be considered that in the present study we have 
re-sequenced well-known genetic determinants of NAFLD not requiring replication. Nevertheless, the analysis 
of rare variants was adjusted for multiple testing.
In conclusion, we confirmed the role of PNPLA3, TM6SF2, GCKR and MBOAT7 gene variants as genetic 
determinants of NAFLD and we suggested a weighted GRS based on their additive and combined effect. We 
believe these results point the way towards a future feasibility of creating comprehensive risk factor panels, in 
which applying genetic testing for the individual-level NAFLD-risk prediction. If definitely confirmed, our GRS 
score could offer the opportunity to exclude low-risk patients from screening tests.
Material and Methods
Study subjects. We studied 445 Caucasian, unrelated subjects, 218 with echographically defined NAFLD 
and 227 healthy controls. The enrollment criteria as well as the protocol for clinical and biochemical charac-
terization of study subjects have been reported elsewhere43. In brief, NAFLD subjects, were considered eligible 
after exclusion of secondary causes of liver steatosis such as previous viral infection, past or present history of 
alcohol abuse (defined as an average daily consumption >20 g/day), use of drugs known to influence the develop-
ment of hepatic steatosis as well as clinical and biochemical evidence of chronic liver diseases. Healthy controls, 
recruited from blood donors, were selected based on the absence of advanced liver disease at ultrasound43. Liver 
ultrasonography was performed with a GE Vivid S6 apparatus equipped with a 3.5-MHz convex-array probe. 
All examinations were done by the same hepatologist and steatosis was assessed semi-quantitatively on a scale of 
0–6: 0, absent; 1, 2 mild; 3, 4 moderate; and 5, 6 severe according to the Hamaguchi criteria44.
The study protocol was reviewed and approved by the Ethics Committee of Sapienza University of Rome, 
Policlinico Umberto I (Rome, Italy). Written informed consent was obtained from all participants in accordance 
with the principles of the Helsinki Declaration. All methods were carried out in accordance with the relevant 
guidelines and regulations.
DNA analysis. Selection of candidate genes. The genes considered for next generation sequencing (NGS) 
were the following: GCKR, NCAN, PPP1R3B, LYPLAL1 and TM6SF2. They were selected because reported by 
GWAS to be associated with NAFLD above a significance threshold of P < 10-4 for any tagging SNPs10,14. In our 
screening, we have also considered the PNPLA3 rs738409 and the MBOAT7 rs641738, as previously demon-
strated to be genetic determinants of NAFLD6,16. The genotyping of these latter variants was performed in dupli-
cate by TaqMan 5′-Nucleotidase assay having a concordance rate of 100%.
Next-generation sequencing (NGS). A custom panel was designed with the help of the AmpliSeq designer online 
tool (https://www.ampliseq.com), which was employed to generate optimized primer designs for the five genes 
present in the human reference genome (hg19). The overall coverage of the design region was 99,9%. (Pipeline 
version 4.2). Amplicon library preparation was performed with the Ion Ampliseq Library kit v2.0 using 10 ng of 
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DNA (Thermo Fisher Scientific). PCR products were partially digested using FuPa reagent, followed by the liga-
tion of barcoded sequencing adapters (Ion Xpress Barcode Adapters kit; Life Technologies, Carlsbad, CA, USA). 
Final libraries were purified using Agencourt AMPure XP magnetic beads (Beckman Coulter, Brea, CA, USA) 
and quantified using a Qubit 3.0 Fluorometer (Thermo Fisher Scientific, Wilmington, DE). The individual librar-
ies were diluted to a final concentration of 100 pM and were pooled and processed to library amplification using 
Ion PGM Template OT2 400 kit. Unenriched libraries were quality-controlled using Ion Sphere quality control 
measurement on a Qubit instrument. Following library enrichment (Ion OneTouch ES), libraries were processed 
for sequencing by using the Ion PGM Hi-Q Sequencing Kit v2.
Data filtering and analysis. Sequencing runs were analyzed using the Torrent Suite v4.4.3 analysis. SNPs and 
insertion/deletions were identified across the targeted subset of the reference genome (hg19) using the analysis 
plug-in Torrent Variant Caller with the parameter settings optimized for germline low stringency and mini-
mal false positive calls. The output variant call format (VCF) file was then annotated through Ion Reporter (Ion 
Reporter™ Software 4.6) and wANNOVAR softwares (http://wannovar.wglab.org). All sequencing variants were 
filtered using our custom NGS pipeline. All variants with Depth Coverage (DP) ≥30, Genotype Quality (GQ) 
≥30, Allele Frequency (AF) ≥33 and ≤50 or ≥70 and ≤100, with balanced Alternate Allele Observations on 
the forward strand (SAF) and Alternate Allele Observations on the reverse strand (SAR) were considered as 
high confident variants and used for further analysis. Twenty four variants in 77 subjects with moderate quality 
were retested by Sanger sequencing on an ABI PRISM 3130 XL Genetic Analyzer following standard protocols. 
Overall, 13 variants with AF <33 and DP <20 were not confirmed.
The damaging effect of identified missense variants were evaluated by in silico prediction softwares. SIFT, 
PolyPhen-2, Provean, SNP&GO and Mutation T@ster Prediction softwares were used. A collective predictive 
score, ranging from 0–10, was calculated as the sum of individual scores of the 5 tools utilized, each being 0 
(Neutral/benign/Polymorphism) or 1 (possibly damaging by Polyphen) or 2 (Disease Causing/Probably 
Damaging). Variants were defined as damaging if reported as deleterious in at least three of five prediction tools.
All common (MAF >5%), low frequency and rare variants (MAF ≥1 or ≤5% and <1%, respectively) anno-
tated as functional (nonsense, frameshift, splice-region and missense) were considered for the analysis.
Power Calculation. Power analysis was performed by the Genetic Association Study (GAS) Power Calculator 
(© 2017 Jennifer Li Johnson | University of Michigan), commonly used to compute statistical power for one-stage 
genetic association studies within the setting of additive or multiplicative genetic models. The prevalence of 
NAFLD in our population was estimated as 0.30 and the odd ratio (OR) for each risk allele of the tested genetic 
variants was set at approximately 2.0, as estimated in previous studies45. Assuming an allele frequency of 0.3 (for 
common variants) and 0.03 (for low-frequency variants) in the general population and an additive model for 
disease risk, with a sample size of 218 cases and 227 controls the expected power under a significance level of 0.05 
was of 100% to identify common genetic associations and 87% to identify low-frequency genetic associations. 
Notably our analysis had a power of 0.80 to detect genetic effects with OR of at least 1.9 for low-frequency and 
1.35 for common variants.
Genetic Risk Score Computation. The Genetic Risk Score (GRS) was calculated based on the four SNPs reaching 
the highest levels of significance for NAFLD: rs1260326 C/T in GCKR, rs58542926 C/T in TM6SF2, rs738409 
C/G in PNPLA3 and rs641738 C/T in MBOAT7 genes. Two methods were used to create the GRS: a simple count 
method (unweighted GRS) and a weighted method (weighted GRS)31,32. The count method assumed that each 
SNP contributed equally to NAFLD risk and was calculated applying a linear weighting of 0, 1 and 2 to genotypes 
containing 0, 1, or 2 risk alleles, respectively. While in our population we found only two homozygous subjects 
for rs58542926 in TM6SF2 gene this produced a score between 0 and 7, representing the maximum total num-
ber of risk alleles. The weighted 4-SNP GRS was calculated by multiplying each β -coefficient for the NAFLD 
phenotype obtained from the Dallas Heart Study6,22 by the number of corresponding risk alleles (0, 1, or 2) and 
then summing the products. The β–coefficient considered for each SNP were: 0.2653 (rs738409 PNPLA3), 0.2711 
(rs58542926 TM6SF2), 0.0649 (rs1260326 GCKR) and 0.0575 (rs641738 MBOAT7). The 4-SNP GRS was mod-
elled as a continuous variable and then categorized into tertiles.
Statistical analysis. The two-sample t-test (for parametric variables) or the Mann–Whitney test (for 
non-parametric variables) was used to compare the difference between case and control groups for quantita-
tive traits, while Pearson’s χ2 test was used to compare discrete traits. Deviations of genotype frequency from 
the Hardy–Weinberg assumption were assessed using a χ2 test. Differences in allele and genotype frequencies 
between cases and controls were assessed by χ2 test under either dominant or recessive model of penetrance.
The enrichment of gene variants was evaluated by counting NAFLD cases and controls positive for at least on 
functional variant in each candidate gene.
Logistic regression analysis (Forward-Wald Statistic or Enter method) were adopted to assess the most signif-
icant model of inheritance for each SNP, the joint effects of genes and clinical variables and to evaluate gene-gene 
and gene-environmental interactions. The adequacy of the final model was assessed using Hosmer-Lameshow 
goodness-of-fit test. Furthermore, the Nagelkerke R2 was calculated to indicate how useful the explanatory 
variables in the model were in predicting NAFLD46. We further analysed the association of PNPLA3 rs738409, 
TM6SF2 rs58542926, GCKR rs1260326 and MBOAT7 rs641738 with biochemical indices by using General Linear 
Model test with bootstrap correction including age and sex as covariates. TG and TC were also adjusted for BMI, 
diabetes and statin therapy while HOMAIR was adjusted for BMI. For variables with skewed distributions (ALT, 
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AST, TG, HOMAIR), a logarithm was applied before analysis to ensure that the residuals were approximately 
normal and had constant variance.
The effect of studied variants as well as of additional risk factors on the degree of hepatic steatosis were ana-
lyzed in logistic regression analysis (Forward-Wald Statistic) by comparing patients with severe NAFLD as having 
Hamaguchi score = 5–6 (N = 71) with patients without or with mild-moderate hepatic steatosis (Hamaguchi 
score = 0–4) (N = 362).
Associations between NAFLD risk and 4-SNP GRS were tested using Pearson correlations or logistic regres-
sion analysis.
Multiple comparisons were adjusted by bootstrap correction based on 1000 bootstrap samples with the aim to 
adjust raw p-value thus obtaining more robust estimates of standard errors and confidence intervals of parame-
ters included in the models. Statistical significance was taken at nominal P-value < 0.05 for all comparisons. All 
analyses were performed using SPSS package (version 22.0) (SPSS, Inc., Chicago, IL, USA).
Data availability statement. All data generated or analyzed during this study are included in this pub-
lished article (and its Supplementary Information files). The datasets generated during and/or analyzed during 
the current study are not publicly available due to the lack of a specific patients’ consent but are made available by 
corresponding author based on reasonable request.
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